01643nas a2200241 4500000000100000008004100001260001700042653003000059653001800089653001100107653002300118653001200141653002500153653003000178100001600208700001800224245006700242300001100309490000700320050003200327520102800359022001401387 2000 d c2000 Oct-Dec10aDrug Therapy, Combination10aGlobal health10aHumans10aLeprostatic Agents10aleprosy10aMycobacterium leprae10aWorld Health Organization1 aal-Qubati Y1 aal-Kubati A S00aMultidrug therapy--the pathway for global leprosy elimination. a477-900 v72 aInfolep Library - available3 a

Introduction of dapsone therapy paved the way for better and more humanitarian way of dealing with the leprosy victims who, prior to 1943, were simply rejected and segregated from society. Emergence of dapsone-resistant M. leprae and mycobacterial persistence provoked our quest for another solution. More drugs were discovered for treatment of leprosy. But the real breakthrough was the recommendation of regimens of multidrug therapy (MDT) for the treatment of leprosy by the WHO Study Group on Chemotherapy of Leprosy in October 1981. Subsequent world wide development of leprosy control activities was phenomenal. The impact of MDT has led to the cure of over eight million leprosy sufferers and the saving of one million patients from becoming crippled. Leprosy prevalence has decreased by 80% in ten years. By the end of May 1999 the leprosy burden remained concentrated in only 12 countries of the world. These achievements are mainly attributed to the development and worldwide adoption of the MDT programme.

 a0254-9395